Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraFRA:TSUA +1.02%69 EBITDA Margin % is 25.15% as of Mar. 2026, which is 6% above its 10-year median of 23.64. GuruFocus rates FRA:TSUA with a GF Score™ of 69/100 and a GF Value™ of €21.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Tsumura ranks better than 84.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tsumura's EBITDA for the
three
months ended in Mar. 2026 was €65 Mil. Tsumura's Revenue for the
three
months ended in Mar. 2026 was €259 Mil. Therefore, Tsumura's EBITDA margin for the quarter that ended in Mar. 2026 was 25.15%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tsumura EBITDA Margin % Related Terms
Tsumura EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tsumura's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tsumura's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura (FRA:TSUA) has a EBITDA Margin % of 25.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tsumura and its competitors. This is near median its historical median of 23.64. Over the past decade, Tsumura's EBITDA Margin % has ranged from 19.97 to 31.61. According to the industry distribution chart, Tsumura ranks #153 out of 961 companies in the Drug Manufacturers industry, placing it in the top 15.9%.
Is Tsumura's EBITDA Margin % too high?
Tsumura's current EBITDA Margin % of 25.15% is near median its 10-year median of 23.64. Over the past 10 years, this metric has ranged from a low of 19.97 to a high of 31.61. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Tsumura's value of 25.15% is 102.2% above this industry median. Based on the distribution chart, Tsumura ranks #153 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tsumura has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tsumura's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #153 out of 961 companies for EBITDA Margin %. This places Tsumura in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Tsumura's value of 25.15% is 102.2% above this benchmark. Historically, Tsumura's own EBITDA Margin % has ranged from 19.97 to 31.61 over the past decade. While the company's 10-year median is 23.64 vs. the industry median of 12.44, Tsumura has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current EBITDA Margin % of 25.15% is 102.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tsumura and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current EBITDA Margin % is 25.15%, which is near median its own 10-year median of 23.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Based on GuruFocus' analysis, Tsumura (FRA:TSUA) is currently considered Fairly Valued. The stock's GF Value™ is €21.71, compared to a current price of €19.80 — trading 8.8% below its estimated fair value. The current EBITDA Margin % is 25.15%, which is near median its 10-year median of 23.64 and 102.2% above the Drug Manufacturers industry median of 12.44. Tsumura's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tsumura (FRA:TSUA), the current EBITDA Margin % is 25.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (FRA:TSUA) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of €19.80 is trading 8.8% below its estimated GF Value™ of €21.71.
GuruFocus considers Tsumura to be Fairly Valued.
Key valuation signals for FRA:TSUA:
EBITDA Margin %: 25.15% (near median its 10-year median of 23.64)
GF Value™: €21.71 vs. price of €19.80 (8.8% below fair value)
Industry Position: 102.2% above the Drug Manufacturers median (#153 of 961)
No single metric tells the full story. See the FRA:TSUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
69GF Score
Get the complete analysis for FRA:TSUA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TSUA has been successfully added to your 
